CD274 and non-small cell lung carcinoma: The therapy based on PD-1/PD-L1 immune checkpoint blockade show a better tolerated than traditional standard chemotherapy in NSCLC patients, but the AEs of these drugs are different from traditional cytotoxic therapy.